| Field | Specification |
|---|---|
| Mfr No | |
| Alternative Names | Protein Bop; BH3-only protein; Retrotransposon Gag-like protein 10; RTL10; BOP, C22orf29 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | A synthetic peptide corresponding to a sequence at the C-terminus of human GRK2, identical to the related mouse and rat sequences. |
| Isotype | |
| Molecular Weight | |
| Product Type | |
| Reactivity | |
| Reconstitution | |
| Target | |
| UniProt # |
Overview
Anti-GRK2 Antibody Picoband® is an antibody for GRK2 detection raised in Rabbit (Polyclonal, Rabbit IgG), with reported reactivity: Human,Mouse,Rat,Monkey. Commonly used in WB, IHC, IF, ICC, Flow Cytometry, ELISA workflows.
Key elements and design rationale
- Target: GRK2 (retrotransposon Gag like 10); UniProt: P25098
- Antibody format: Rabbit, Polyclonal, Rabbit IgG
- Molecular weight: 80 kDa, calculated 14377 MW
- Applications: WB, IHC, IF, ICC, Flow Cytometry, ELISA
Vendor description (summary): Boster Bio Anti-GRK2 Antibody Picoband® catalog # A32388-1.
Biological background
Biological context: Could induce apoptosis in a BH3 domain-dependent manner. The interaction network of Bcl-2 family members may play a key role in modulation RTL10/BOP intrinsic apoptotic signaling activity.
Expression and localization notes: cellular localization: Cell membrane; Lipid-anchor, GPI-anchor., tissue context: Ubiquitously expressed..
Common research applications
- Western blotting (WB): Compare GRK2 levels across samples and conditions using appropriate loading and biological controls.
- Immunohistochemistry (IHC): Evaluate spatial distribution of GRK2 in tissue sections, considering fixation and antigen retrieval effects.
- Immunofluorescence / ICC: Assess subcellular localization patterns and co-localization with compartment markers in cultured cells.
- Flow cytometry: Quantify GRK2-positive populations in single-cell suspensions with appropriate gating and controls.
- ELISA: Use antibody-based detection formats to assess antigen presence or binding in plate-based assays.
Notes for experimental interpretation
- Account for isoforms, post-translational modifications, and sample-specific processing that can shift apparent molecular weight or epitope accessibility.
- Use positive/negative biological controls where possible (e.g., known-expressing cells/tissues, knockdown/knockout models) and include appropriate secondary-only/isotype controls for imaging workflows.
Additional product notes (from provided fields)
- Background: Beta adrenergic receptor kinase (also referred to as βARK or BARK) is a serine/threonine intracellular kinase. The product of this gene phosphorylates the beta-2-adrenergic receptor and appears to mediate agonist-specific desensitization observed at high agonist concentrations. This protein is an ubiquitous cytosolic enzyme that specifically phosphorylates the activated form of the beta-adrenergic and related G-protein-coupled receptors. Abnormal coupling of beta-adrenergic receptor to G protein is involved in the pathogenesis of the failing heart.
- Cross reactivity: No cross-reactivity with other proteins.
- Cellular localization: Cell membrane; Lipid-anchor, GPI-anchor.
- Tissue details: Ubiquitously expressed.
- Research category: Chemokines,Immunology,Innate Immunity
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
